- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07570316
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease (VitaliThy)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs
The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it.
The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment.
The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment.
More information can be found here: https://clinicaltrials.argenx.com/vitalithy
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Sabine Coppieters, MD
- Número de telefone: 857-350-4834
- E-mail: clinicaltrials@argenx.com
Locais de estudo
-
-
California
-
Carlsbad, California, Estados Unidos, 92012
- Recrutamento
- Profound Research LLC at Tri-City Primary Care
-
Contato:
- Jamil Alkhaddo, MD
- Número de telefone: 419-681-0637
- E-mail: jamil.alkhaddo@profoundresearch.com
-
Orange, California, Estados Unidos, 92868
- Recrutamento
- Diabetes Associates Medical Group
-
Contato:
- Ivy-Joan Madu, MD
- Número de telefone: 714-202-8894
- E-mail: diabetesmd@sbcglobal.net
-
Pasadena, California, Estados Unidos, 91101
- Recrutamento
- Pasadena Clinical Trials
-
Contato:
- Tzu-Jen Tzao
- Número de telefone: 5206127860
- E-mail: ttzao@pasadenatrials.com
-
Pasadena, California, Estados Unidos, 91105
- Recrutamento
- Havana Research Institute LLC.
-
Contato:
- John De Beixedon, MD
- Número de telefone: 626-698-9794
- E-mail: drjohn@havanaresearchinstitute.com
-
San Jose, California, Estados Unidos, 95128
- Recrutamento
- San Jose Clinical Trials
-
Contato:
- Richard Cherlin
- Número de telefone: 408-358-2663
- E-mail: rcherlin@sanjosetrials.com
-
-
Florida
-
Fleming Island, Florida, Estados Unidos, 32003
- Recrutamento
- Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park Location
-
Contato:
- Senan Sultan, MD
- Número de telefone: 478-319-7900
- E-mail: drsultan@nerifl.com
-
Fort Lauderdale, Florida, Estados Unidos, 33312
- Recrutamento
- The Center for Diabetes and Endocrine Care
-
Contato:
- Sam Lerman, MD
- Número de telefone: 954-963-7100
- E-mail: slerman@diabetes-endocare.com
-
Jacksonville, Florida, Estados Unidos, 32256
- Recrutamento
- University of Florida Jacksonville College of Medicine
-
Contato:
- Christian Koch
- Número de telefone: +1 857-350-4834
- E-mail: Christian.Koch@jax.ufl.edu
-
Kissimmee, Florida, Estados Unidos, 34744
- Recrutamento
- Ilumina Medical Research LLC
-
Contato:
- Max Sosa-Pagan, MD
- Número de telefone: 857-350-4834
- E-mail: MSosapaganMD@gmail.com
-
Miami, Florida, Estados Unidos, 33144
- Recrutamento
- Oceane 7 Medical & Research Center, Inc
-
Contato:
- Orlando Fernandez
- Número de telefone: 305 261 2738
- E-mail: o.fernandez.oceane7@gmail.com
-
-
Kansas
-
Lenexa, Kansas, Estados Unidos, 66219
- Recrutamento
- Johnson County Clin-Trials, Inc.
-
Contato:
- Thomas Kreamer, MD
- Número de telefone: 913-825-4400
- E-mail: tkreamer@jcct.com
-
Wichita, Kansas, Estados Unidos, 67226
- Recrutamento
- Alliance for Multispecialty Research, LLC
-
Contato:
- Terry Klein
- Número de telefone: 316-689-6629
- E-mail: terry.klein@amr-clinical.com
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Recrutamento
- University of Michigan
-
Contato:
- Tae-Hwa Chun
- Número de telefone: 734-615-5420
- E-mail: taehwa@med.umich.edu
-
Dearborn, Michigan, Estados Unidos, 48126
- Recrutamento
- Metro Detroit Endocrinology Center
-
Contato:
- Ayman Elkadry, MD
- Número de telefone: 313-203-5300
- E-mail: aymankad73@gmail.com
-
Farmington Hills, Michigan, Estados Unidos, 48334
- Recrutamento
- Profound Research
-
Contato:
- Gary Edelson, MD
- Número de telefone: 947-254-1920
- E-mail: gary.edelson@profoundresearch.io
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64108
- Recrutamento
- Truman Medical Center
-
Contato:
- Rajib Bhattacharya, MD
- Número de telefone: +1 857-350-4834
- E-mail: rajib.bhattacharya@uhkc.org
-
-
New York
-
Albany, New York, Estados Unidos, 12203
- Recrutamento
- Albany Medical College Community Endocrinology
-
Contato:
- Robert Busch
- Número de telefone: 518 489 4704
- E-mail: thyroiddoc@aol.com
-
New York, New York, Estados Unidos, 10016
- Recrutamento
- Endocrine Associates of West Village PC
-
Contato:
- Anastasios Manessis, MD
- Número de telefone: 646-660-9991
- E-mail: amanessis@endocrinenyc.com
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 28803
- Recrutamento
- Asheville Clinical Research
-
Contato:
- Lauren Bernstein
- Número de telefone: +1 857-350-4834
- E-mail: bbernstein@ashevilleclinicaltrials.com
-
Raleigh, North Carolina, Estados Unidos, 27612
- Recrutamento
- Wake Internal Medicine Consultants
-
Contato:
- Juman Takeddin, MD
- Número de telefone: 919-781-7500
- E-mail: jtakeddin@wakeinternalmedicine.com
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75231
- Recrutamento
- Research Institute of Dallas
-
Contato:
- Heidi Shea, MD
- Número de telefone: 927-867-4658
- E-mail: hshea@eadallas.com
-
El Paso, Texas, Estados Unidos, 79935
- Recrutamento
- Frontier Medical Center - Academy of Diabetes Thyroid and Endocrine
-
Contato:
- Sergio Rovner
- Número de telefone: 915-633-9387
- E-mail: sergiorovner@hotmail.com
-
Houston, Texas, Estados Unidos, 77040
- Recrutamento
- Juno Research
-
Contato:
- Damaris Vega, MD
- Número de telefone: 713-779-5494
- E-mail: Dvega@jcct.com
-
Houston, Texas, Estados Unidos, 77089
- Recrutamento
- Clinic of Endocrinology
-
Contato:
- Amir Hassan, MD
- Número de telefone: 281-944-3610
- E-mail: amir@biopharmainfo.net
-
Irving, Texas, Estados Unidos, 75039
- Recrutamento
- Tekton Research Irving
-
Contato:
- Pablo Mora, MD
- Número de telefone: 972-566-7799
- E-mail: pablo.mora@tektonresearch.com
-
McAllen, Texas, Estados Unidos, 78503
- Recrutamento
- Biopharma Informatic, LLC
-
Contato:
- Gloria Ortiz, MD
- Número de telefone: 281-944-3610
- E-mail: gortiz@biopharmainfo.net
-
McKinney, Texas, Estados Unidos, 75069
- Recrutamento
- Tekton Research - McKinney
-
Contato:
- Muhammad Siddiqui, MD
- Número de telefone: 972-777-6011
- E-mail: muhammad.siddiqui@tektonresearch.com
-
Mesquite, Texas, Estados Unidos, 75149
- Recrutamento
- Southern Endocrinology Associates PA
-
Contato:
- Sumana Gangi, MD
- Número de telefone: 214-909-8904
- E-mail: sumana_gangi@yahoo.com
-
Shavano Park, Texas, Estados Unidos, 78231
- Recrutamento
- Consano Clinical Research
-
Contato:
- Daniel Katselnik, MD
- Número de telefone: 210-545-4900
- E-mail: katselnik.md@consanosa.com
-
-
-
-
-
Tbilisi, Geórgia, 0114
- Recrutamento
- New Hospitals
-
Contato:
- Lia Katcharava, MD
- Número de telefone: +995 599530278
- E-mail: likakatcharava@yahoo.com
-
Tbilisi, Geórgia, 0102
- Recrutamento
- LLC American Hospital Network
-
Contato:
- Nino Gabidzashvili, MD
- E-mail: endo.advice@gmail.com
-
Tbilisi, Geórgia, 0119
- Recrutamento
- LLC Todua Clinic
-
Contato:
- Tamar Khutsishvili, MD
- E-mail: Khutsishvilitamar1@outlook.com
-
Tbilisi, Geórgia, 0112
- Recrutamento
- LTD Israeli-Georgian Medical Research Clinic Healthycore
-
Contato:
- Miranda Baratashvili, MD
- E-mail: baratashvilimiranda@gmail.com
-
Tbilisi, Geórgia, 0159
- Recrutamento
- In Vitro Fertilization Center LLC
-
Contato:
- Tea Khurodze, MD
- E-mail: khurodze@yahoo.com
-
-
-
-
Tyne and Wear
-
Gateshead, Tyne and Wear, Reino Unido, NE9 6SX
- Recrutamento
- Queen Elizabeth Hospital (Gateshead Health NHS Foundation Trust)
-
Contato:
- Syed Salman Razvi
- Número de telefone: +44 191 445 6052
- E-mail: salman.razvi@newcastle.ac.uk
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF.
- Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels >=ULN (upper limit of normal) at screening.
- Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) <0.1 mIU/L at screening.
- Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening.
Exclusion Criteria:
- History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter).
- History of RAI (radioactive iodine) therapy or received a total thyroidectomy.
- T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received <6 weeks before screening.
- Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications.
- Graves' orbitopathy/Thyroid Eye Disease (GO/TED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and/or planned corrective surgery/irradiation or medical therapy during the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Part A - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period. |
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS) |
|
Comparador de Placebo: Part A - placebo PH20 SC PFS
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period. |
Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS) |
|
Experimental: Part B - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period. |
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS) |
|
Experimental: Part B - placebo PH20 SC PFS
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period. |
Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS) |
|
Experimental: Part C - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period |
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS) |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A
Prazo: Up to 24 weeks (part A)
|
Free triiodothyronine: [fT3]; free thyroxine: [fT4]; ATDs: antithyroid drugs |
Up to 24 weeks (part A)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time to becoming euthyroid
Prazo: Up to 24 weeks (part A) + up to 135 weeks
|
Up to 24 weeks (part A) + up to 135 weeks
|
|
|
Efgartigimod serum concentrations over time
Prazo: Up to 24 weeks (part A) + 72 weeks (part C)
|
Up to 24 weeks (part A) + 72 weeks (part C)
|
|
|
Time to becoming euthyroid off ATDs in part A
Prazo: Up to 24 weeks (part A)
|
ATDs: antithyroid drugs |
Up to 24 weeks (part A)
|
|
Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A
Prazo: Up to 24 weeks (part A)
|
MMI: methimazole (also known as thiamazole); CBZ: carbimazole. |
Up to 24 weeks (part A)
|
|
Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A
Prazo: Up to 24 weeks (part A)
|
ULN : upper limit of normal; ATDs: antithyroid drugs. |
Up to 24 weeks (part A)
|
|
Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A
Prazo: Up to 24 weeks (part A)
|
TRAb: anti-TSHR autoantibodies; ATDs: antithyroid drugs. |
Up to 24 weeks (part A)
|
|
Time to becoming euthyroid off ATDs and TRAb seronegative
Prazo: Up to 24 weeks (part A) + up to 135 weeks
|
ATDs: antithyroid drugs; TRAb: anti-TSHR autoantibodies. |
Up to 24 weeks (part A) + up to 135 weeks
|
|
Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A)
Prazo: Up to 24 weeks (Part A)
|
ATDs: antithyroid drugs; MMI: methimazole (also known as thiamazole); CBZ: carbimazole. |
Up to 24 weeks (Part A)
|
|
Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A)
Prazo: Up to 24 weeks (part A)
|
TSH: thyroid-stimulating hormone; LLN: lower limit of normal. |
Up to 24 weeks (part A)
|
|
Percentage of participants who remain euthyroid without ATDs
Prazo: Up to 74 weeks (part B)
|
ATDs: antithyroid drug |
Up to 74 weeks (part B)
|
|
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS for 6, 12, and 18 months
Prazo: Up to 74 weeks (part B) + up to 135 weeks
|
ATDs: antithyroid drug |
Up to 74 weeks (part B) + up to 135 weeks
|
|
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS
Prazo: Up to 72 weeks (part C)
|
ATDs: antithyroid drug |
Up to 72 weeks (part C)
|
|
Incidence of AEs and SAEs
Prazo: Up to 135 weeks
|
AEs: adverse events ; SAEs: serious adverse events. |
Up to 135 weeks
|
|
Change in ThyPRO-39 over time
Prazo: Up to 135 weeks
|
The Thyroid-Specific Patient-Reported Outcome Short Form (ThyPRO-39) 39 item version of the ThyPRO. Each item is related to a specific aspect of the participant's experience with their thyroid condition. Each item is scored on a 5-point Likert scale, and the scores are then transformed to a 0-to-100 scale. Higher scores indicate worse health status. |
Up to 135 weeks
|
|
Change in PROMIS-PF10a over time
Prazo: Up to 135 weeks
|
The Patient-Reported Outcomes Measurement Information System Physical Function-10 item (PROMIS-PF10a) is a self-administered physical functioning assessment comprising 10 items that measure respondents' ability to perform common physical tasks. Scoring involves summing the numerical responses to each item; higher scores indicate better physical function. |
Up to 135 weeks
|
|
Percentage change from baseline in total IgG levels in serum over time
Prazo: Up to 98 weeks
|
IgG: immunoglobulin G |
Up to 98 weeks
|
|
Percentage change from baseline in TRAb serum levels over time
Prazo: Up to 135 weeks
|
TRAb: anti-TSHR autoantibodies. |
Up to 135 weeks
|
|
Incidence of ADA against efgartigimod in serum
Prazo: Up to 24 weeks (part A) + up to 135 weeks
|
ADA: antidrug antibody(ies) |
Up to 24 weeks (part A) + up to 135 weeks
|
|
Incidence of antibodies against rHuPH20 in plasma
Prazo: Up to 24 weeks (part A) + Up to 135 weeks
|
rHuPH20: recombinant human hyaluronidase PH20 |
Up to 24 weeks (part A) + Up to 135 weeks
|
|
Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma
Prazo: Up to 24 weeks (part A) + up to 135 weeks
|
NAb: neutralizing antibody(ies); rHuPH20: recombinant human hyaluronidase PH20. |
Up to 24 weeks (part A) + up to 135 weeks
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ARGX-113-25-GRD-3002
- 2025-524223-42-00 (Ctis)
- 2025 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .